Altasciences' companies, Preclinical Services in Seattle, Algorithme Pharma, Vince and Associates Clinical Research, and Algorithme Pharma USA, are now further united under the Altasciences brand.
According to the company, feedback from clients and third parties made it clear that its current brand identity did not fully convey the company's approach, capabilities, expertise and, in particular, the efforts put in to integrating their capabilities and sites with the goal of providing a coordinated approach to early phase development.
As a result, Altasciences has aligned its brand with who they are and what they do: Moving in Unison to deliver big impact with a personal touch.
The brand logo, which has green ribbons moving together in a peak to form an 'A', symbolizes the company's dedication to working together to maintain the highest scientific and operational standards necessary to meet clients' challenges, while always seeking new opportunities to innovate. Green represents the color of life, growth, harmony, and success.
A refreshed graphic approach features imagery that represents real-life moments, demonstrating the vibrancy of life and the essence of what Altasciences does, supporting research that helps bring new medicines to the people who need them, faster. The new identity has been fully rolled out in a revamped company website.
Altasciences is a mid-size contract research organisation offering pharmaceutical and biotechnology companies a flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept.
For over 25 years, Altasciences has been integrating into clients' projects to help support educated, faster, and more complete early drug development decisions.
Altasciences' full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, programme management, medical writing, biostatistics, and data management.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA